Disclosures. You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies. 9/20/17

Similar documents
Conflict of Interest Disclosure

Urine Drug Testing to Monitor Opioid Use In Managing Chronic Pain

Disclosures. Get Your Specimens in Order:

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

September HCMC Toxicology Transition: Additional information and Frequently Asked Questions

10 mg hydrocodone equals how much oxycodone

URINE DRUG TOXICOLOGY

Prior Authorization Guideline

See Important Reminder at the end of this policy for important regulatory and legal information.

Urine Drug Testing. Methadone/Buprenorphine 101 Workshop. Ron Joe, MD, DABAM December 10, 2016

Fighting the Good Fight: How to Convert Opioids Just Right!

The Utility of Urine Drug Screening

3/8/2018. Reasons for Doing UDT. UDT: A Tool in Risk Assessment. Faculty/Presenter Disclosure. Urine Drug Testing in Chronic Pain Management

Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization

Overview. Opioids and HIV Infection: From Pain Management to Addiction Treatment

Laboratory Testing to Support Pain Management: Methods, Concepts and Case Studies

Session VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable

10/9/18. Learning Objectives. Get Your Specimens in Order: The Importance of Individualized Test Orders and Timely Test Utilization

Conversion chart from fentanyl to opana er

: Opioid Quantity Limits

Pain Management Wrap-Up Chronic Care. David Tauben, MD Medicine Anesthesia & Pain Medicine

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

1/27/ New Release, Quest Diagnostics Nichols Institute, Valencia

MEDICAL POLICY Drug Testing

2015 Annual Physician Notice

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

What Your Drug Test Really Means. Krista Beiermann, RN, OHS Occupational Health Services, Columbus Hospital

Subject: Pain Management (Page 1 of 7)

THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

EXTENDED RELEASE OPIOID DRUGS

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Controlled Substance Monitoring in the Age of the Opioid Epidemic

Using Liquid Chromatography Tandem Mass Spectrometry Urine Drug Testing to Identify Licit and Illicit Drug-Use in a Community-based Patient Population

3703 Camino del Rio South 100-A San Diego, CA, Phone Fax CLIA# 05D years

MEDICAL POLICY Drug Testing

Welcome - we will begin the webinar shortly Please read the participation tips below:

Urine drug testing it s not always crystal clear

Session II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids

Testing for Controlled Substances

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

Laboratory Service Report

Long-Acting Opioid Analgesics

Effective Date: Approved by: Laboratory Executive Director, Ed Hughes (electronic signature)

Long-Acting Opioid Analgesics

Blueprint for Prescriber Continuing Education Program

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Gold Standard for Urine Drug Testin Urine Drug Testing Why U rine? Urine?

See Important Reminder at the end of this policy for important regulatory and legal information.

Urine Drug Testing Methods 3-5

Walking the Line: Opioid Dose De-escalation

Pharmacy Medical Necessity Guidelines: Opioid Analgesics

Dose equivalent of fentanyl patch to oxycontin

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE

Opioid Analgesic Treatment Worksheet

SCG1 Evaluation of High Risk Pain Medications for MME

Drug Screening: Things You Need to Know

B. Long-acting/Extended-release Opioids

Opioid Analgesic Treatment Worksheet

Objectives. When to Refer. PISA Physicians 1/25/17. Financial Disclosures: None. PISA & THMEP January 28, 2017 Kenneth B. Gossler M.D.

New Product to Market: Lonhala Magnair

Pain Management and Compliance Toxicology. Greg Jellick, MSFS, D-ABFT-FT Technical Director Quality Toxicology San Antonio, TX

Morphine equivalent calculator suboxone

PACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION. Chronic Pain and Opiate Management Initiatives

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

Recent Developments in FRA s Post-Accident Toxicological Testing Program

Inconspicuous and Miscalculated Opioid Risks Plus Updates on Rescheduling Hydrocodone

Urine Drug Testing (UDT) to Monitor Opioid Use. Feb 2018

OAT Transitions - focus on microdosing. Mark McLean MD MSc FRCPC CISAM DABAM

Opioid Case Studies. Thomas P. Pittelkow, D.O., M.P.H. Mayo Clinic College of Medicine Rochester, MN. September 29, MFMER slide-1

Prescribing drugs of dependence in general practice, Part C

WELCOME! 12/13/2018. Today s Topic: Urine Drug Screens in OUD Treatment UW PACC

5/10/17. Back to Basics: The Role of Chronic Opioids for Chronic Pain. Thomas B. Gregory, PharmD, BCPS, FASPE, CPE. Disclosures. Nothing to disclose

nextgen precision Test Report

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

A brief history of urine drug testing. Forging a common vocabulary for urine drug testing

Prior Authorization for Opioid Products Indicated for Pain Management

Managing Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.

See Important Reminder at the end of this policy for important regulatory and legal information.

TITLE: Guidelines for Treatment of Chronic Pain EFFECTIVE DATE: LAST REVISED DATE: LAST REVIEWED DATE:

Urine Opioid Dependency Panel (UODP) 1

Up and Away with Opioids

Knock Out Opioid Abuse in New Jersey:

Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary

15mg oxycodone is equivalent to how much morphine

Pain Medication Management Program Supports Patient Outcomes and Adherence

Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory

PROFESSIONALISM AND COMMENTARY. Optimizing Urine Drug Testing for Monitoring Medication Compliance in Pain Management

CLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics

The Drug Testing Process. Employer or Practice

Opioid Conversions Mixture of Science and Art

Opioid Management of Chronic (Non- Cancer) Pain

Urine Drug Testing (UDT) in Pain Management. Nov 27, 2017

Patient-Centered Urine Drug Testing. Douglas Gourlay, MD, MSc, FRCPC, FASAM

Kentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations

Linking Opioid Treatment in Primary Care. Roxanne Lewin M.D.

Urine Drug Testing (UDT) in Pain Management. Nov 5, 2017

Overview of the AACC Academy s LMPG: Using clinical laboratory tests to monitor drug therapy in pain management patients

Transcription:

You're in Control or Urine Control Clinical Pearls of Drug Testing Case Studies Jeffrey Fudin, BS, PharmD, FCCP, FASHP www.paindr.com Disclosures Astra Zeneca (Speakers Bureau) Collegium (Consultant) Daiichi Sankyo (Advisory Board) DepoMed (Advisory Board, Speakers Bureau) Egalet (consultant, Advisory Board)) Endo (Consultant, Speakers Bureau) Iroko Pharmaceuticals (Speakers Bureau) Pernix Therapeutics (Speaker) Quest Labs (Advisory Board) Remitigate, LLC (Owner) 1

Learning Objectives Differentiate between in-office qualitative testing and laboratory quantitative testing Explain how to interpret unexpected UDT results Explain how to incorporate UDT results into ongoing clinical assessment and decision making Describe how to communicate with patients about unexpected results in a positive, therapeutic manner 3 Street Value Perspective 120 Percocet 5/325 (brand name) $600.00 120 Lortab 10/500 (any brand) $600.00 60 Oxycontin 80mg $1500.00 120 Actiq Lollipop 200mcg $3240.00 Knowing when your patient is diverting drug PRICELESS! http://streetrx.com/ 2

The Whizzinator Kit http://www.thewhizzinator.com/lifestyle-products/lilwhizz Urine Drug Testing (UDT) Rationale Guidelines recommend UDT as standard of care when prescribing chronic opioid therapy, especially for CNCP3-7 Helps to ensure compliance and mitigate risk3-7 Detects presence of illicit substances Detects absence of prescribed medication Helps to justify continual prescriptions Supports clinician decision to discontinue controlled substance medication 3

Urine Drug Testing (UDT) Rationale Supports justification for closer monitoring (more frequent visits / lab monitoring) Supports behavior modification and referral to psychologist Potential Pitfalls8-11 Patient reliability to report compliance, use and misuse is dubious and often poor Behavior alone is unreliable for identifying patients at risk non-compliance, abuse, misuse, and diversion Types of Urine Drug Testing Immune Assay (IA) In office or send out Inexpensive Results are quick (minutes) Helps for initial detection False negatives/positives False patient accusations Easier for pts to manipulate low sensitivity, esp w/ synthetics Presence/absence of RX class only No option for synthetics, designer drugs, and unique natural products Chromatography Usually send-out More expensive 24 hours to 1 week (per lab) Final result Definitive testing Justifies RX decisions 99.999 percent reliability high sensitivity Presence/absence of RX metabolites Custom option for synthetics, designer drugs, and unique natural products 4

Opioid Chemistry and Cross-sensitivity 12 Opioid and Benzodiazepine Metabolites plus Validity Testing http://www.remitigate.com/resources/ 10 5

Opioids and Benzodiazepine Metabolites (continued from previous slide) Addressing Unexpected Results False or Unexpected Discuss findings with patient Confirm false positive (as a true negative) to support and document patient s integrity and compliance Confirm unexpected positive to justify ADT products, and or other RX adjustments (partial agonist, partial agonist/antagonist, etc.) substance abuse counseling Alternative and other behavior health intervention False Confirm false negative (as a true positive) to support and document patient s integrity and compliance Reisfield GM,Goldberger, BA, Bertholf RL. False-positive and false-negative test results in clinical urine drug testing. Bioanalysis 2009. 1(5): 937-52. 6

Select Opioid Analgesic Choices Extended Release Products: Buprenorphine Transdermal Patch Buprenorphine Buccal Film Fentanyl Transdermal Patch Hydrocodone ER Hydromorphone-ER Morphine-ER (several products available) Oxycodone-ER Oxymorphone-ER Synthetic Atypical: Long Biological T1/2 & intermediate analgesic T1/2 Levorphanol Methadone Case Study 1 Face Pain 43 year old Caucasian male TMJ and trigeminal neuralgia Failed NSAIDs, cartilage implants, nerve blocks, iontophoresis Past Medical History (PMH): + Hep C, but otherwise inconsequential Current pharmacologic regimen includes: Gabapentin 1200mg PO TID Hydrocodone ER 20mg PO QAM Oxycodone tabs 5mg, 1 PO TID PRN 7

Case Study 1 Face Pain What do these results mean? Test Opiate IA In-Office Results Result Gabapentin 1200mg PO TID Hydrocodone ER 20mg PO QAM Oxycodone tabs 5mg, 1 PO TID PRN Chromatography [send out] Results Test Oxycodone Hydrocodone Gabapentin Result Case Study 1 Unexpected Results for Prescribed Medications Lack of oxycodone PRN use pharmacokinetics (when was urine collected?) Noncompliance Test is not specific for the drug tested (opiate vs. synthetic) Drug-drug, drug-disease, drug-food/supplement interactions Genetic polymorphism 8

Case Study 1 Face Pain Speak with patient Give patient an opportunity to explain Assessment: Document justification for plan Devise actionable medical plan based on lab findings Change in drug therapy (Patch, ADF, no opioid) Justification for f/u lab testing Justification for alternative therapies Justification for behavioral health Case Study 2 Chronic Back Pain 50 year old Caucasian female History of chronic low back pain with justifiable pathology Back surgery x 3 (failed back) PMH: chronic pain, depression, hypothyroidism Current pharmacologic regimen includes: Duloxetine 60mg PO QAM Fentanyl 50mcg/hr changed Q72 hours Hydrocodone + APAP 5/325, 1 PO Q4H PRN 9

Case Study 2 Chronic Back Pain What do these results mean? IA In-Office Results Test Opiate Benzodiazepines Benzoylecgonine (cocaine metabolite) Result Duloxetine 60mg PO QAM Fentanyl 50mcg/hr changed Q72 hours Hydrocodone + APAP 5/325, 1 PO Q4H PRN Chromatography [send out] Results Test Fentanyl Hydrocodone Alphahydroxyalprazolam Benzoylecgonine Result Case Study 2 Unexpected Results for Prescribed Medications for unprescribed and illicits Lack of hydrocodone PRN use Pharmacokinetics (when was urine collected?) Noncompliance (illegally obtained drugs) Test is not specific for the drug tested (opiate vs. synthetic, in this case fentanyl) Drug-drug, drug-disease, drug-food/supplement interactions Genetic polymorphism 10

Case Study 3 Lower Chest & Abdominal Pain for Prescribed Medications False for Unprescribed and Illicits 33 year old American Indian male Lung cancer, now free of disease Chronic upper abdominal & chest pain following his original tumor resection and radiation PMH: depression Current pharmacologic regimen includes: Morphine 90mg PO QAM Venlafaxine ER 225mg PO QAM Case Study 3 Unexpected Results What do these results mean? In-Office Test Results Test Opiate Phencyclidine (PCP) Result Morphine 90mg PO QAM Venlafaxine ER 225mg PO QAM LC-MS/MS Laboratory Test Results Test Morphine Hydromorphone Phencyclidine (PCP) Venlafaxine Result 11

Knowledge of P-Kinetics is Essential Morphine Metabolism Phase II Glucuronidation by UGT2B7 M3G (morphine-3-glucuronide) M6G (morphine-6-glucuronide) Less than 5% hydromorphone Case Study 3 Unexpected Results Patient was compliant with Morphine Venlafaxine PCP was false positive because of venlafaxine Hydromorphone confirmation unexpected? It is a rare metabolite of morphine Educate patient and clearly document in the chart 12

Case Study 4 Icing on the Cake Drugs: Butrans 15mg TD Patch, changed Qweek Quetiapine 50mg PO QHS Alprazolam 0.5mg PO TID Ibuprofen 600mg PO TID PRN Case Study 4 Unexpected Results What do these results mean? In-Office Test Results Test Opiate Buprenorphine Benzodiazepine Cannabinoid Methadone Butrans 15mg TD Patch, changed Q week Quetiapine 50mg PO QHS Alprazolam 0.5mg PO TID Ibuprofen 600mg PO TID PRN Result LC-MS/MS Laboratory Test Results Test Buprenorphine, norbuprenorphine, buprenorphineglucuronide, and norbuprenorphineglucuronide Alphahydroxyalprazolam Cannabinoid Methadone Result 13

Case Study 4 What does it mean? Buprenorphine is a POTENT synthetic opioid and will not test positive for IA opiate screen at most buprenorphine TD doses opiate screen would indicate that the patient was using another unprescribed drug Alprazolam generally will not test positive on an IA test Alprazolam and buprenorphine were confirmed by definitive test results Quetiapine may cause false positive methadone Ibuprofen may cause false positive cannabinoid Software Help to Interpret and document ia UDT results Della Volpe K. New App Helps Interpret Urine Drug Test Results. Practical Pain Management. 2015 July/Aug; 15(6); 84-87. Available: http://www.practicalpainmanagement.com/resources/diagnostic-tests/new-app-helps-interpret-urine-drug-testresults 14

With permission, Remitigate LLC Della Volpe K. New App Helps Interpret Urine Drug Test Results. Practical Pain Management. 2015 July/Aug; 15(6); 84-87. Available: http://www.practicalpainmanagement.com/resources/diagnostic-tests/new-app-helps-interpret-urine-drug-test-results With permission, Remitigate LLC 15

With permission, Remitigate LLC Patient s RX s include Hydrocodone 20mg per day Alprazolam 2mg per day Venlafaxine 250mg per day Naproxen 1000mg per day 32 16

With permission, Remitigate LLC With permission, Remitigate LLC 17

With permission, Remitigate LLC With permission, Remitigate LLC 18

With permission, Remitigate LLC With permission, Remitigate LLC 19

Paste to Chart Opioids Test result not unexpected because total dose of synthetic opioids may be too low for detection. Urintel recommends discussing finding with patient, using clinical judgement, and if indicated, definitive testing by quantitative confirmation. Benzodiazepines Test result is not unexpected because the prescribed benzodiazepine(s) can provide a negative result. Urintel recommends discussing finding with patient, using clinical judgement, and if indicated, definitive testing by quantitative confirmation. Amphetamines Test Amphetamines positive result not expected since amphetamines are not prescribed. Recommend discussing with patient. Click here for a list of potential false positives. Urintel recommends discussing finding with patient, using clinical judgement, and if indicated, definitive testing by quantitative confirmation. Barbiturates Test result expected because no barbiturate was prescribed. Cannabinoids Test result unexpected because cannabinoid(s) is(are) not prescribed and a false positive was not detected. Click here for list of false positives. Urintel recommends discussing finding with patient, using clinical judgement, and if indicated, definitive testing by quantitative confirmation. Cocaine Test result expected. PCP Test result not unexpected because false positive, venlafaxine, detected. Click here for a full list of false positives. Urintel recommends discussing finding with patient, using clinical judgement, and if indicated, definitive testing by quantitative confirmation. WARNING: RISK OF OPIOID TOXICITY INCLUDING RESPIRATORY DEPRESSION, OVERDOSE, AND DEATH ARE ELEVATED WHEN COMBINING OPIOIDS WITH BENZODIAZEPINES OR BARBITUATES. IF CLINICALLY WARRANTED, CONSIDER TAPERING OPIOIDS OR THE SEDATIVE-HYPNOTIC. In high risk patients, even with a negative urine screen, it is recommended to quantify results by chromatography for definitive testing including synthetic cathinones (Bath Salts) and synthetic cannabinoids (Spice). This is because synthetic cannabinoids generally are not revealed by immune assay in-office testing. Consider ordering other 'designer' or natural substances such as Kratom in high risk patients. With permission, Remitigate LLC How does this affect you? Accurately found taking more drug than prescribed an old prescription drug someone else s prescription an illicit drug Falsely accused of taking unprescribed drug not taking prescribed drug taking illicit drugs Definitive Chromatography test may be warranted! 20

Questions? 21